Alumis: Envudeucitinib Delivered Highest PASI 100 Skin Clearance In Plaque Psoriasis
Alumis Inc. (ALMS) reported long-term extension results from its ONWARD3 study of envudeucitinib, an investigational oral TYK2 inhibitor for plaque psoriasis. It said 54% of patients reached PASI 100 at 48 weeks and 75% reached PASI 90, with durability in responders and no new safety signals. ALMS plans an FDA NDA submission in Q4 2026.
How this was made
The 30-second read
Why it matters
The newest disclosed facts are ONWARD3 long-term extension efficacy (PASI 100/90 rates at 48 weeks), durability among responders, and the stated plan to submit an FDA NDA in Q4 2026. These can shift probability-weighted expectations for eventual approval and commercial positioning, but do not constitute regulatory approval or a definitive label timeline.
Market read
Traders may treat this as a positive clinical read-through for ALMS, with a tangible next milestone (NDA in Q4 2026) that can influence medium-term positioning.
What to watch
The article does not disclose absolute safety details, discontinuation rates, or head-to-head/comparator context; traders may wait for full dataset, subgroup durability, and regulatory interaction signals before repricing risk.
Background
Alumis is developing envudeucitinib, an investigational oral TYK2 inhibitor for plaque psoriasis, with ONWARD1-3 studies evaluating efficacy, durability, and safety.
Ticker impact
Alumis reported ONWARD3 long-term extension results for envudeucitinib, with 54% achieving PASI 100 at 48 weeks and plans for an FDA NDA in Q4 2026.
Near-term upside bias possible on sentiment, but magnitude likely limited until NDA filing details, regulatory feedback, or additional confirmatory endpoints emerge.
The article provides specific efficacy percentages and durability, plus a concrete regulatory milestone (NDA in Q4 2026). However, it is still investigational and lacks FDA interaction or approval timing, which caps immediate fundamental impact.
Market effects
Adds incremental competitive data for oral TYK2 inhibitor candidates in plaque psoriasis, potentially influencing expectations for efficacy and durability benchmarks across the class.
Primarily US biotech sentiment, with potential spillover to other dermatology-focused developers in US pre-market/early session.
Supports global psoriasis treatment landscape expectations, though the immediate catalyst is company-specific and US regulatory oriented.
Counterpoint
High PASI 100 rates in an extension study may not fully translate to label outcomes, and “highest among oral therapies” is comparative and may depend on cross-trial assumptions.
Key entities
- companyAlumis Inc.
Sponsor of envudeucitinib and the issuer announcing ONWARD3 long-term extension results and an FDA NDA plan.
- drug_candidateEnvudeucitinib
Investigational oral TYK2 inhibitor for plaque psoriasis; reported PASI 100/90 outcomes and durability in ONWARD3.
- clinical_trialONWARD3 study
Long-term extension dataset used to report PASI 100/90 response rates and durability through 48 weeks.
- medical_expertDr. Mark Lebwohl
Quoted clinical therapeutics dean commenting on the potential for reliable, durable disease control in an oral format.
